We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Datar Cancer Genetics, a cancer research company, today announced positive data from the phase II/III RESILIENT trial intended to validate clinical benefit for cancer patients ...